← All trials
NCT05863585
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2023
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2025
- First posted
- May 18, 2023
- Last posted
- May 18, 2023
- Enrollment
- 14
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- International AIDS Vaccine InitiativeLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Access to Advanced Health Institute (AAHI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.